CN105943655A - 一种治疗痔疮复方膏剂及制备方法 - Google Patents
一种治疗痔疮复方膏剂及制备方法 Download PDFInfo
- Publication number
- CN105943655A CN105943655A CN201610287136.4A CN201610287136A CN105943655A CN 105943655 A CN105943655 A CN 105943655A CN 201610287136 A CN201610287136 A CN 201610287136A CN 105943655 A CN105943655 A CN 105943655A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- hemorrhoid
- water
- weight
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000014617 hemorrhoid Diseases 0.000 title claims abstract description 59
- 239000002674 ointment Substances 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 22
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 19
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 claims abstract description 16
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940095100 fulvic acid Drugs 0.000 claims abstract description 16
- 239000002509 fulvic acid Substances 0.000 claims abstract description 16
- 241000628997 Flos Species 0.000 claims abstract description 14
- 239000002671 adjuvant Substances 0.000 claims abstract description 14
- 239000004615 ingredient Substances 0.000 claims abstract description 14
- 239000000454 talc Substances 0.000 claims abstract description 14
- 235000012222 talc Nutrition 0.000 claims abstract description 14
- 229910052623 talc Inorganic materials 0.000 claims abstract description 14
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 11
- -1 liquid paraffin Chemical compound 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000012047 saturated solution Substances 0.000 claims description 10
- 238000009833 condensation Methods 0.000 claims description 5
- 230000005494 condensation Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 230000035876 healing Effects 0.000 abstract description 7
- 208000016583 Anus disease Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract description 2
- 230000010261 cell growth Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 2
- 229940116229 borneol Drugs 0.000 abstract 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 235000021018 plums Nutrition 0.000 abstract 2
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 10
- 201000007772 internal hemorrhoid Diseases 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000436 anus Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000002605 anti-dotal effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000004021 humic acid Substances 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003077 lignite Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 201000007783 perianal hematoma Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开一种治疗痔疮的复方膏剂及其制备方法,属于中药技术领域。所述膏剂包括辅料和中药成分,所述中药成分为黄腐酸25~35重量份、龙骨10~20重量份、黄芩5~10重量份、槐花8~10重量份、乌梅10~15重量份、滑石10~15重量份、冰片1~2重量份。辅料为:β‑环糊精、硬脂酸镁,液状石蜡,甘油,三乙醇胺,水。本发明所述膏剂含有黄腐酸、黄芩、龙骨子、槐花、乌梅、滑石、冰片等中草药成分,通过中草药的配伍禁忌,用药的合理搭配,很好的起到消炎止血,促进细胞的生长,加快痔疮的愈合,减少痔疮复发;其能有效的治疗外痔、内痔混合痔等多种肛门疾病;原料天然,制作简单,成本低廉,副作用小,效果显著。
Description
技术领域
本发明涉及一种治疗痔疮的复方膏剂及其制备方法,属于中药技术领域。
背景技术
痔疮是一种常见疾病,它是由于人体直肠末端粘膜下和肛管皮肤下静脉丛发生扩张和屈曲所形成的柔软静脉团,是一种常见的肛肠疾病。按发生部位的不同分为内痔、外痔、混合痔。外痔可分为结缔组织性外痔、静脉曲张性外痔、血栓性外痔;兼有内痔和外痔的为混合痔,是内痔通过静脉丛与相应的外痔融合,即上、下静脉丛的吻合,混合痔脱出肛门外,呈梅花状时,称为环形痔,若被括约肌嵌顿,形成嵌顿性痔。痔疮任何年龄都可发病,但随着年龄增长,发病率逐渐增高。在我国,痔是最常见的肛肠疾病,素有“十男九痔”、“十女十痔”的说法。痔疮的常见症状有出血、血栓水肿、疼痛等。
目前,临床针对痔疮,有多种治疗手段,主要有药物治疗、物理治疗和手术治疗,其中手术治疗价格贵、恢复慢、易复发,严重还会有大便失禁后遗症等诸多缺点。而非手术治疗采用局部用药治疗 已被广泛采用,药物包括栓剂、膏剂和洗剂,多数含有中药成分。内服外用治疗痔疮的中西药种类很多,但目前现有的临床治疗效果来看,疗效慢、疗程长、复发率高,部分药对人体有一定副作用。
发明内容
本发明的目的在于针对现有技术的不足,提供一种治疗痔疮的复方膏剂,所述膏剂包括辅料和中药成分,所述中药成分为黄腐酸25~35重量份、龙骨10~20重量份、黄芩5~10重量份、槐花8~10重量份、乌梅10~15重量份、滑石10~15重量份、冰片1~2重量份。
本发明所述辅料为:β-环糊精8~10重量份、硬脂酸镁10~12重量份、液状石蜡5~7重量份,甘油5~8重量份,三乙醇胺1~3g重量份,水100~200重量份。
本发明的另一目的在于提供所述治疗痔疮的复方膏剂的制备方法,具体包括以下步骤:
(1)取龙骨、黄芩、槐花、乌梅、滑石,混合均匀后粉碎后过100目筛,按混合物与水质量比为1:2~1:3的比例加水浸泡20~24h,先用开水煮沸后文火煎煮0.5~1h后加入黄腐酸,最后加入冰片,冰片煮5分钟即可;煎煮2~3次,合并煎煮液,冷却浓缩成浸膏,冷冻干燥;
(2)按0.4~0.5g/mL的比例将步骤(1)得到的浸膏溶解在质量百分比为95~100%的乙醇中得到浸膏液,另将β-环糊精溶解在100~150mL水中,70~80℃水浴60min,待其完全水解后,在40~45℃水浴条件下制成饱和溶液,将β-环糊精饱和溶液慢慢滴入浸膏液中,持续搅拌2~3小时得到白色混悬液,静置过夜、抽滤,然后用95~100%乙醇洗涤沉淀1~2次,将沉淀物于45~50℃下干燥,得粉末状包合物;
(3)取包合物、硬脂酸镁、液状石蜡、甘油、水进行混合,然后在95~100℃水浴中进行搅拌,待其完全溶解后加入三乙醇胺,搅拌至冷凝,即得治疗痔疮的膏剂。
本发明所述黄腐酸参照专利申请200810233669.X“褐煤氧化降解生产腐殖酸及其盐的方法”中的方法并经过纯化制得腐殖酸。
本发明的治疗痔疮乳膏配方有黄腐酸配黄芩具有清热解毒,燥湿,抗炎止血,消炎杀菌,二者相合止痛解毒,共为君药;龙骨,乌梅,槐花涩肠,泻火清热,生肌敛疮,解毒消肿、攻坚散结通经止痛而泻火、止血不留瘀、活血不伤正、其解疮毒为臣药;滑石、冰片解毒疗疮、止痛透窍为佐药;辅料调合众药,又起润燥作用为使药;诸药合用才能充分发挥止痛解毒、清热消肿、攻坚散结、止血活血、代瘀通洛的功能作用。
本痔疮乳膏制成环糊精包合物,能被体吸收利用,无蓄积毒性作用。外用,涂搽患处,且疗效显著,毒副作用小。
本发明膏剂使用时根据痔疮的类型,外痔将药上到痔疮的病灶上以药全部覆盖病灶为度;内痔将插嘴插入肛齿线内约2厘米注药适量;混合痔用上述二法同时给药;用药时间要求12小时换药一次,用药前局部常规清洗、洗后即可用药,如须要解便、便后清洗再给药,一定要保持用药时间,特殊患者可在晚睡前用药,但这样用药对于治疗效果会有影响;用药期间禁止饮酒、吃辣食物,或带有刺激性食物。这样可对临床治疗上有益于药物的全面发挥起到协助作用。
本发明的有益效果:
(1)本发明所述膏剂含有黄腐酸、黄芩、龙骨子、槐花、乌梅、滑石、冰片等中草药成分,通过中草药的配伍禁忌,用药的合理搭配,很好的起到消炎止血,促进细胞的生长,加快痔疮的愈合,减少痔疮复发;其能有效的治疗外痔、内痔混合痔等多种肛门疾病;原料天然,制作简单,成本低廉,副作用小,效果显著。
(2)本发明方法提取工艺简单,操作简单,生产周期短。
具体实施方式
下面通过实施例对本发明方法作进一步详细说明,但本发明方法的保护范围不局限于所述内容。
实施例1
本实施例治疗痔疮的复方膏剂包括辅料和中药成分,所述中药成分为黄腐酸25g、龙骨10g、黄芩10g、槐花8g、乌梅10g、滑石12g、冰片2g。
本实施例所述辅料为:β-环糊精8g、硬脂酸镁10g、液状石蜡7g,甘油5g,三乙醇胺1gg,水100mL。
本实施例所述治疗痔疮的复方膏剂的制备方法,具体包括以下步骤:
(1)取龙骨、黄芩、槐花、乌梅、滑石,混合均匀后粉碎后过100目筛,按混合物与水质量比为1:2的比例加水浸泡20h,先用开水煮沸后文火煎煮0.5h后加入黄腐酸,最后加入冰片,冰片煮5分钟即可;煎煮3次,合并煎煮液,冷却浓缩成浸膏,冷冻干燥;
(2)按0.4g/mL的比例将步骤(1)得到的浸膏溶解在质量百分比为99%的乙醇中得到浸膏液,另将β-环糊精溶解在100mL水中,75℃水浴60min,待其完全水解后,在40℃水浴条件下制成饱和溶液,将β-环糊精饱和溶液慢慢滴入浸膏液中,持续搅拌2小时得到白色混悬液,静置过夜、抽滤,然后用95%乙醇洗涤沉淀2次,将沉淀物于48℃下干燥,得粉末状包合物;
(3)取包合物、硬脂酸镁、液状石蜡、甘油、100mL水进行混合,然后在98℃水浴中进行搅拌,待其完全溶解后加入三乙醇胺,搅拌至冷凝,即得治疗痔疮的膏剂。
实施例2
本实施例治疗痔疮的复方膏剂包括辅料和中药成分,所述中药成分为黄腐酸30g、龙骨15g、黄芩8g、槐花10g、乌梅12g、滑石10g、冰片1g。
本实施例所述辅料为:β-环糊精10g、硬脂酸镁11g、液状石蜡5~7g,甘油5~8g,三乙醇胺1~3g,水200mL。
本实施例所述治疗痔疮的复方膏剂的制备方法,具体包括以下步骤:
(1)取龙骨、黄芩、槐花、乌梅、滑石,混合均匀后粉碎后过100目筛,按混合物与水质量比为1:3的比例加水浸泡24h,先用开水煮沸后文火煎煮1h后加入黄腐酸,最后加入冰片,冰片煮5分钟即可;煎煮2次,合并煎煮液,冷却浓缩成浸膏,冷冻干燥;
(2)按0.5g/mL的比例将步骤(1)得到的浸膏溶解在质量百分比为98%的乙醇中得到浸膏液,另将β-环糊精溶解在100mL水中,80℃水浴60min,待其完全水解后,在42℃水浴条件下制成饱和溶液,将β-环糊精饱和溶液慢慢滴入浸膏液中,持续搅拌3小时得到白色混悬液,静置过夜、抽滤,然后用98%乙醇洗涤沉淀2次,将沉淀物于50℃下干燥,得粉末状包合物;
(3)取包合物、硬脂酸镁、液状石蜡、甘油、200mL水进行混合,然后在98℃水浴中进行搅拌,待其完全溶解后加入三乙醇胺,搅拌至冷凝,即得治疗痔疮的膏剂。
实施例3
本实施例治疗痔疮的复方膏剂包括辅料和中药成分,所述中药成分为黄腐酸35g、龙骨20g、黄芩5g、槐花9g、乌梅15g、滑石15g、冰片1.5g。
本实施例所述辅料为:β-环糊精9g、硬脂酸镁12g、液状石蜡5g,甘油8g,三乙醇胺3g,水200mL。
本实施例所述治疗痔疮的复方膏剂的制备方法,具体包括以下步骤:
(1)取龙骨、黄芩、槐花、乌梅、滑石,混合均匀后粉碎后过100目筛,按混合物与水质量比为1:2的比例加水浸泡22h,先用开水煮沸后文火煎煮0.7h后加入黄腐酸,最后加入冰片,冰片煮5分钟即可;煎煮3次,合并煎煮液,冷却浓缩成浸膏,冷冻干燥;
(2)按0.45g/mL的比例将步骤(1)得到的浸膏溶解在质量百分比为95%的乙醇中得到浸膏液,另将β-环糊精溶解在125mL水中,70℃水浴60min,待其完全水解后,在45℃水浴条件下制成饱和溶液,将β-环糊精饱和溶液慢慢滴入浸膏液中,持续搅拌3小时得到白色混悬液,静置过夜、抽滤,然后用95%乙醇洗涤沉淀1次,将沉淀物于45℃下干燥,得粉末状包合物;
(3)取包合物、硬脂酸镁、液状石蜡、甘油、250mL水进行混合,然后在95℃水浴中进行搅拌,待其完全溶解后加入三乙醇胺,搅拌至冷凝,即得治疗痔疮的膏剂。
本发明实施例1~3复方中药对小鼠有效性实验如下:
将体重在180~220g的昆明雄鼠30只,取滤纸,将其制成内径为6mm的滤纸片,放入99%醋酸溶液中浸泡,将浸泡后的滤纸片放到模型组和乳膏组大鼠肛门周围,使滤纸片紧密接触肛周皮肤及粘膜,每次用一片滤纸,每只大鼠持续2min,0.5min时换一次滤纸,每只大鼠共用两张纸片。24h后观察大鼠肛门,发现该部位红肿,灼伤,甚至出血,有溃疡液,即造模成功,之后根据灼伤的严重程度将大鼠平均分为三组,即模型组,实验组和阳性组。
模型组不给药。实验组于大鼠肛周溃疡处抹黄腐酸乳膏,每次0.2g,每天两次,连续用药十天。阳性组:于大鼠肛周溃疡处涂抹马应龙痔疮膏,每次0.2g,每天两次,连续用药十天。观察溃疡面红肿,组织炎性渗出,及溃疡面的愈合时间。评定溃疡程度,有溃疡渗出液1分,有少量渗出液2分,有焦痂、基本愈合3分。计量以均数±标准差表示,采用SPSS17.0统计分析软件分析。两组间数据比较采用t检验,以p<0.01为差异统计学意义。
表1 各组不同时间肛周溃疡评分(n=10)
结果:与模型组比较,实验组与阳性药大鼠于第七天溃疡开始愈合(*P<0.05),第十天明显较模型组愈合效果好(**P<0.01)。
下面通过在临床上的使用说明本实施例1~3制备得到的膏剂的临床疗效:临床上对40例病理观察,其中男性20人,女性20人,年龄为20~40岁的痔疮患者,内痔、外痔、混合痔在患者中均存在。通过使用本发明药物,37人有效,有效率88%,30人治愈,治愈率达到75%。
典型病例:
病例1 李某,男,30岁,昆明本地村民,内痔3年患者02年12月26日到医院就诊,为内痔,肛门出血疼痛,买了市场上的药膏疗效差,易复发,后用了本发明实施例进行治疗,所有临床上的证状全部消失,后坚持用药现在一直保持这种状况。
病例2 孙某某,男,41岁,本地村民,患混痔21年,零六年11月26日前去医院就诊,这次发病以一周多,前几次发病用过荣昌肛泰和马应药膏自述没有效果,查混合痔核1.5cm×2.5cm另还有三枚外痔核大小不等,最小的有0.5cm×0.8cm十分痛苦,睡不安吃不香,用实施例软膏给药治疗,三天后喜来告知所有证状以去十分有七,看痔核也消有一半,一月后街上偶遇主动告知;二疗程用完所有病证完无,直到今年九月没复发。
病例3.刘某某,40岁出租车司机,患混合痔16年自述痔核鸡蛋黄大小,进五年平均每年发病一次,每次必住院一周以上,苦不堪言,曾用过很多外用药,建议用实施例的软膏,这次以发病2天是抱着试试看的心态,当日给药二疗程,按医嘱说明使用,20天后来电话告知药没用完彻底全愈。
上述三例患者在使用本发明治疗时,均告知停止使用任何药治疗,患者在使用本发明时最好是全日体息治疗,这样能保持患者在每天24小时内都能正常用药,充分全面的发挥出本发明的功能作用及实施效果,使患者在使用本发明的治疗期间能够达到最佳的预期治疗目的。
Claims (3)
1.一种治疗痔疮的复方膏剂,其特征在于,所述膏剂包括辅料和中药成分,所述中药成分为黄腐酸25~35重量份、龙骨10~20重量份、黄芩5~10重量份、槐花8~10重量份、乌梅10~15重量份、滑石10~15重量份、冰片1~2重量份。
2.根据权利要求1所述治疗痔疮的复方膏剂,其特征在于,所述辅料为:β-环糊精8~10重量份、硬脂酸镁10~12重量份、液状石蜡5~7重量份,甘油5~8重量份,三乙醇胺1~3g重量份,水100~200重量份。
3.权利要求1或2所述治疗痔疮的复方膏剂的制备方法,其特征在于,具体包括以下步骤:
(1)取龙骨、黄芩、槐花、乌梅、滑石,混合均匀后粉碎后过100目筛,按混合物与水质量比为1:2~1:3的比例加水浸泡20~24h,先用开水煮沸后文火煎煮0.5~1h后加入黄腐酸,最后加入冰片,冰片煮5~6分钟即可;煎煮2~3次,合并煎煮液,冷却浓缩成浸膏,冷冻干燥;
(2)按0.4~0.5g/mL的比例将步骤(1)得到的浸膏溶解在质量百分比为95~100%的乙醇中得到浸膏液,另将β-环糊精溶解在100~150mL水中,70~80℃水浴60min,待其完全水解后,在40~45℃水浴条件下制成饱和溶液,将β-环糊精饱和溶液慢慢滴入浸膏液中,持续搅拌2~3小时得到白色混悬液,静置过夜、抽滤,然后用95~100%乙醇洗涤沉淀1~2次,将沉淀物于45~50℃下干燥,得粉末状包合物;
(3)取包合物、硬脂酸镁、液状石蜡、甘油、水进行混合,然后在95~100℃水浴中进行搅拌,待其完全溶解后加入三乙醇胺,搅拌至冷凝,即得治疗痔疮的膏剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610287136.4A CN105943655A (zh) | 2016-05-04 | 2016-05-04 | 一种治疗痔疮复方膏剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610287136.4A CN105943655A (zh) | 2016-05-04 | 2016-05-04 | 一种治疗痔疮复方膏剂及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105943655A true CN105943655A (zh) | 2016-09-21 |
Family
ID=56913609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610287136.4A Pending CN105943655A (zh) | 2016-05-04 | 2016-05-04 | 一种治疗痔疮复方膏剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105943655A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113769038A (zh) * | 2021-10-11 | 2021-12-10 | 于菲 | 一种高效吸收的肛肠疾病外用药膏 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027965A (zh) * | 2013-01-06 | 2013-04-10 | 罗智勇 | 一种治疗痔疮的中药组合物及制备方法 |
CN103432497A (zh) * | 2013-09-10 | 2013-12-11 | 于浩 | 一种治疗痔疮的外用制剂 |
CN104398868A (zh) * | 2014-10-30 | 2015-03-11 | 昆明理工大学 | 一种治疗痔疮的复方中药 |
CN105012535A (zh) * | 2015-08-12 | 2015-11-04 | 广州中大药物开发有限公司 | 一种防治肛周疾病组合物及其制备方法 |
CN105213518A (zh) * | 2014-02-08 | 2016-01-06 | 吴杰 | 保健品 |
-
2016
- 2016-05-04 CN CN201610287136.4A patent/CN105943655A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027965A (zh) * | 2013-01-06 | 2013-04-10 | 罗智勇 | 一种治疗痔疮的中药组合物及制备方法 |
CN103432497A (zh) * | 2013-09-10 | 2013-12-11 | 于浩 | 一种治疗痔疮的外用制剂 |
CN105213518A (zh) * | 2014-02-08 | 2016-01-06 | 吴杰 | 保健品 |
CN104398868A (zh) * | 2014-10-30 | 2015-03-11 | 昆明理工大学 | 一种治疗痔疮的复方中药 |
CN105012535A (zh) * | 2015-08-12 | 2015-11-04 | 广州中大药物开发有限公司 | 一种防治肛周疾病组合物及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113769038A (zh) * | 2021-10-11 | 2021-12-10 | 于菲 | 一种高效吸收的肛肠疾病外用药膏 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101843687B (zh) | 一种治疗痔疮的中药制剂及其制备方法 | |
CN101049466B (zh) | 治疗烧烫伤的中草药膏及其制备方法 | |
CN110339249B (zh) | 一种用于痔疮肛裂的中药组合物及其制备方法和应用 | |
CN105943655A (zh) | 一种治疗痔疮复方膏剂及制备方法 | |
CN102836342A (zh) | 一种治疗痔疮的中药 | |
CN103977173A (zh) | 一种治疗痤疮的中药汤剂 | |
CN101455771A (zh) | 一种治疗痔病的中药外用软膏药剂 | |
CN102872188B (zh) | 一种治疗痔疮的内服药物及其制备方法 | |
CN101513478B (zh) | 一种治疗ⅲ期脉管炎的外敷药膏 | |
CN104623304A (zh) | 一种治疗湿热毒蕴型慢性皮肤溃疡的洗剂及其制备方法 | |
CN104971332A (zh) | 一种治疗痔疮中药 | |
CN103948709B (zh) | 一种维吾尔药热合美康宫栓剂及其制备方法 | |
CN104398868B (zh) | 一种治疗痔疮的复方中药 | |
CN102697978A (zh) | 一种治疗痔疮的外洗中药组合物 | |
CN102309625B (zh) | 一种治疗痔疮疾病的中药组合物及其药液的制备方法 | |
CN101700297B (zh) | 一种治疗痔疮的药物 | |
CN101647938B (zh) | 一种治疗烧烫伤的药物及其制备方法 | |
CN101244174B (zh) | 一种治疗脉管炎的药物及其制备方法 | |
CN111329923A (zh) | 一种治疗痔疮的中药制剂及其制备方法 | |
CN102908467B (zh) | 一种治疗血尿的中药药物 | |
CN110652548A (zh) | 一种治疗痔疮的中药及其制备方法 | |
CN116059305A (zh) | 一种治疗子宫肌瘤的药物组合物 | |
CN103272042A (zh) | 治疗痔瘘的熏洗剂 | |
CN102657704A (zh) | 一种治疗痔疮的凉茶及其制备方法 | |
CN114767741A (zh) | 一种消肿止痛的中药外敷组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |